trending Market Intelligence /marketintelligence/en/news-insights/trending/-1ozLo8mdraXZd_-qR8NxA2 content esgSubNav
In This List

ThromboGenics shareholders approve name change

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


ThromboGenics shareholders approve name change

Belgium-based biotechnology company ThromboGenics NV gained shareholders approval to change its name to Oxurion NV at an extraordinary general meeting held Sept. 3.

ThromboGenics' lead product JETREA is used to treat declining visual function due to vitreomacular traction syndrome.

The company's ticker on Euronext Brussels will change to OXUR from THR.

ThromboGenics said in a statement that it will also change its corporate website in connection with the name change.